I am often asked what my favorite dividend stock is.  

So I want to share the one single stock that's by far my favorite right now.

Unlike many dividend-paying companies... which rely on boring income through utilities, rent or oil...

This company owns the bestselling drug in the world, which brought in $19.9 billion in revenue last year.

And it has a pipeline of other blockbuster drugs, which are expected to generate $35 billion in sales.

It doesn't take a genius to know that healthcare is at the forefront of everyone's mind right now, including the folks on Wall Street.

Last year, this company's stellar drug sales allowed it to pay shareholders $5.6 billion in dividends.

That's cash you can claim a piece of.

And today, I want to give you the name, the ticker symbol and my full analysis completely free - no strings attached. 

Click here to get it.

Sincerely,

Marc Lichtenfeld

Chief Income Strategist, The Oxford Club

P.S. When I say FREE, I mean it. There is no catch. You get my entire Ultimate Dividend Package... including my No. 1 dividend stock... free of charge. Here's how.

This ad is sent on behalf of The Oxford Club. 105 W Monument St, Baltimore, Maryland 21201. 

If you would like to optout from receiving offers from The Oxford Club please click here.

This email is a paid advertisement. It is for a product and/or service that is not offered, recommended or endorsed by Stocks on the Run and neither the company nor its affiliates bear responsibility or control over the content of the advertisement and the product or service offered. There is a very high degree of risk involved in trading. Past performance is not indicative of future results. The profits and performance shown are not typical, we make no future earnings claims, and you may lose money. Stocks on the Run and all individuals affiliated with this site assume no responsibility for your trading and investment results. The indicators, strategies, columns, articles and all other features are strictly for communication purposes only and should not be construed as investment advice. Information for any trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. Your information may be shared with our educational partners. You must assess the risk of any trade with your licensed investment professional and make your own independent decisions regarding any securities or investments mentioned herein. Affiliates of Stocks on the Run may have a position or effect transactions in the securities or investments described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

This email was sent to newsletter@newslettercollector.com. Don't want to receive these emails anymore? Unsubscribe here.

Stocks on the Run  |  a Dynamic Web Services Inc DBA MediaPub web property | 101 Marketside Ave. Suite 404 PMB 318 Ponte Vedra, FL 32081